title: Increased protein-conjugated acrolein and amyloid-β40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease.
abstract: The objective of this study was to determine whether plasma levels of acrolein, a compound that causes cell damage, and amyloid-β (Aβ) are useful biochemical markers for Alzheimer's disease (AD). The study included 221 elderly subjects divided into 101 non-demented [33 healthy control and 68 non-demented subjects with white matter hyperintensity (nd-WMH)], 50 mild cognitive impairment (MCI), and 70 AD. Increases in both protein-conjugated acrolein (PC-Acro) and Aβ40/42 ratio were observed in MCI and AD patients compared with values in control subjects. When the combined measurements of PC-Acro and Aβ40/42 ratio were evaluated using the median value of the relative risk value for dementia, they were in the order AD (0.98) ≥ MCI (0.97) > nd-WMH (0.83) > control (0.35). The results indicate that measurements of PC-Acro and Aβ40/42 ratio not only detect MCI and AD patients but also nd-WMH subjects. Furthermore, both PC-Acro and Aβ40/42 ratio in plasma for 120 MCI and AD patients were significantly higher than those for 101 control and nd-WMH subjects, indicating that both values become useful biochemical markers for MCI and AD subjects.
authors: Higashi-Matsudo City Hospital, Matsudo, Chiba, Japan.
authors: Masaaki
authors: M
authors: Waragai
authors: Madoka
authors: M
authors: Yoshida
authors: Mutsumi
authors: M
authors: Mizoi
authors: Ryotaro
authors: R
authors: Saiki
authors: Keiko
authors: K
authors: Kashiwagi
authors: Kiyoshi
authors: K
authors: Takagi
authors: Hiroyuki
authors: H
authors: Arai
authors: Jun
authors: J
authors: Tashiro
authors: Makoto
authors: M
authors: Hashimoto
authors: Naomichi
authors: N
authors: Iwai
authors: Kenichi
authors: K
authors: Uemura
authors: Kazuei
authors: K
authors: Igarashi
mesh_terms: D000171:Acrolein / Q000097:blood*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood* / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000097:blood*; D001284:Atrophy; D015415:Biomarkers / Q000097:blood; D001921:Brain / Q000473:pathology; D002097:C-Reactive Protein / Q000378:metabolism; D060825:Cognitive Dysfunction / Q000097:blood* / Q000473:pathology; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D015850:Interleukin-6 / Q000097:blood; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010446:Peptide Fragments / Q000097:blood*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D015850:Interleukin-6; D010446:Peptide Fragments; C538897:amyloid beta-protein (40-42); D000171:Acrolein; D002097:C-Reactive Protein